Spanish Lab Eliminates Pancreatic Cancer in Mice

Scientists in Spain have achieved something remarkable in the fight against pancreatic cancer. Using a combination of three existing drugs, researchers completely eliminated tumors in laboratory mice with the most aggressive form of the disease.

The team at Spain's National Cancer Research Centre spent six years developing this approach. Lead researcher Mariano Barbacid, who helped discover the first human cancer gene in the 1980s, published the findings in January in the Proceedings of the National Academy of Sciences.

The results stand out because pancreatic cancer is notoriously difficult to treat. Fewer than one in ten patients survive five years after diagnosis, making it one of the deadliest cancers globally.

The triple-drug therapy combines gemcitabine, all-trans retinoic acid, and neratinib. Each drug attacks the cancer differently: one targets rapidly dividing cells, another weakens the protective tissue around tumors, and the third blocks growth signals.

What makes this approach special is how it prevents cancer cells from adapting. Barbacid has long argued that single drugs fail because pancreatic cancer finds alternative ways to survive and grow.

The therapy focused on tumors driven by KRAS gene mutations, which appear in more than 90% of pancreatic cancer cases. This gene has puzzled scientists for decades because it seemed impossible to target effectively.

Even more encouraging, the tumors didn't return after treatment stopped. The mice also tolerated the therapy well with low toxicity, a crucial factor for any potential human trials.

Why This Inspires

This research represents decades of persistence paying off. Barbacid's career-long focus on understanding how cancer adapts and survives has led to a strategy that outsmarts the disease at its own game.

The approach uses drugs that already exist rather than requiring entirely new medications. This could potentially speed up the path to human trials if safety testing continues to show promise.

While experts caution that success in mice doesn't guarantee the same results in people, the scientific community has taken notice. Human cancers are more complex, influenced by factors that don't exist in laboratory settings.

Medical professionals responding to the study online emphasized an important distinction. This is very good news and an important scientific milestone, but it's not yet a cure for humans.

The next phase involves additional safety testing and validation. If regulators approve, early-stage human clinical trials could follow, marking the beginning of a long but hopeful journey.

For the millions of families touched by pancreatic cancer, this research offers something precious: a new direction forward in a fight that has challenged medicine for generations.